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Adrenergic Excess, hNET1 Down-Regulation, and
Compromised mIBG Uptake in Heart Failure
Poverty in the Presence of Plenty*
Nezam Haider, PHD,† Ragavendra R. Baliga, MD, MBA,‡ Y. Chandrashekhar, MD,§
Jagat Narula, MD, PHD†
Long Beach, California; Columbus, Ohio; and Minneapolis, MinnesotaAn increased adrenergic drive contributes to aug-
mented myocyte contractility and altered peripheral
vasoreactivity in heart failure (HF) and appears
intuitively compensatory (1). The increased adren-
ergic contents in the synaptic cleft eventually result
in desensitization of the post-synaptic myocardial
See page 64
adrenergic receptors (2), cardiac remodeling, wors-
ening HF, poor exercise tolerance, increased sus-
ceptibility to arrhythmias, and sudden cardiac death
(3). Systemic norepinephrine (NE) levels correlate
with mortality (4,5), and the beneficial effects of
beta-receptor blockade in HF support the role of
the adrenergic system in the progression and patho-
physiology of HF (6–9).
In the sympathetic neuron, tyrosine is actively
delivered into the axoplasm, where it is converted to
dopamine by cytoplasmic enzymes. Dopamine is
then transported to intraneuronal vesicles where
NE is synthesized and stored (Fig. 1). The action
potential at the nerve terminal triggers the release of
NE in the synaptic cleft, where it activates the
post-synaptic beta1-adrenergic receptors on the sar-
colemmal membrane of the cardiac myocyte; cleft
NE also activates the pre-synaptic 2a- and 2c-
adrenergic receptors to inhibit further NE release.
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.
From the †Memorial Heart and Vascular Institute, University of Califor-
nia Irvine, Long Beach, California; ‡Ross Heart Hospital, Ohio State
University, Columbus, Ohio; and the §Veterans Administration Hospital,
University of Minnesota, Minneapolis, Minnesota. H. William Strauss,
MD, served as Guest Editor for this paper.Almost all NE is actively removed from the synap-
tic cleft by a transporter, human norepinephrine
transporter 1 (hNET1).
In patients with HF, there are increased quanti-
ties of NE in the synaptic cleft. A small proportion
of this NE spills into the bloodstream (increasing
plasma NE levels), and the remainder is transported
by hNET1 back into the axoplasm. However, there
is gradual down-regulation of the transporter and
increased levels of cleft NE, an excess that results in
further impairment of NE reuptake (10). This
concept has been best portrayed by radionuclide
metaiodobenzylguanidine (mIBG) imaging; mIBG
is an NE analog that demonstrates storage, trans-
port, and reuptake characteristics similar to NE in
sympathetic neurons.
Reduced NE reuptake results in low mIBG
concentration in the neurons, and the accelerated
release kinetics lead to an enhanced mIBG washout
rate. In clinical imaging, myocardial mIBG labeled
with radioactive iodine uptake is commonly quan-
tified in terms of the heart to mediastinal (H/M)
uptake ratio. The lowest H/M (or the highest
washout rate) in patients with HF is associated with
the worst prognosis; mIBG uptake has been pro-
posed to be a superior predictor of outcomes than
left ventricular (LV) ejection fraction or B-type
natriuretic peptide. Beta-blockers have been shown
to improve myocardial retention of mIBG (11,12),
and the improved mIBG uptake correlates with the
morphologic characteristics of reverse remodeling.
In this issue of iJACC, Drakos et al. (13) em-
ployed mIBG imaging to substantiate the role of
the adrenergic system in both the pathogenesis and
recovery of patients with HF. A markedly reduced
mIBG uptake in end-stage HF was substantially
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72eversed by unloading of the ventricle after left
entricular assist device (LVAD) implantation; the
/M mIBG uptake ratio on delayed images and the
ashout rate were both significantly improved.
hese results suggest that LVAD restore NE re-
ptake mechanisms. These data are consistent with
ur recent observations of the significant reduction
n hNET1 expression in myocardial samples ob-
ained from patients with advanced HF and marked
mprovment after ventricular unloading with
VAD.
To determine the status of hNET1 expression in
nd-stage HF, we analyzed 8 hearts explanted from
eart transplant recipients, 4 with idiopathic dilated
nd 4 with ischemic cardiomyopathy; hNET1 ex-
ression in cardiomyopathic hearts was compared
ith 8 unused donor (normal) hearts. We deter-
ined hNET1 protein levels by immunoblot anal-
sis; hNET1 protein expression was significantly
educed in HF hearts compared with control hearts
p  0.001) (Figs. 2A and 2B). We also analyzed
aired specimens from 5 additional patients before
E Cascade From Synthesis to Vesicular Storage, Release Into
left, Reuptake, and Partial Inactivation
yl cyclase; COMT  catechol-o-methyltransferase; DA  dopa-
G  dihydroxyphenylglycol; DOPA  dihydroxyphalanine; MAO 
e oxidase; NE  norepinephrine; NMN  normetanephrine.nd after LVAD placement. The hNET1 protein aas virtually absent in 4 of 5 pre-LVAD cardiac
issues, and the post-LVAD samples showed a
ramatic increase in the hNET1 proteins levels
p  0.05) (Figs. 3A and 3B). The molecular data
ndicated the feasibility of restoration of hNET1
xpression in assisted hearts.
Norepinephrine-induced endoplasmic reticulum
tress and an impaired post-translational glycosyla-
ion of NET can accelerate its degradation and may
esult in lower hNET density in HF. To elucidate
his possibility, we analyzed the hNET glycosyla-
ion profile in normal and HF tissues. There was no
ifference in NET1 glycosylation in normal and HF
earts (Fig. 2C), suggesting that there was no
efect in surface expression of hNET on the sarco-
emma. Almost all of the hNET protein was gly-
osylated in these heart samples; a barely detectable
nglycosylated fraction of hNET was present in the
upernatant.
It is expected that the superfluous NE in the
ynaptic cleft will normally be efficiently reab-
orbed by the hNET1. In fact, patients with 2c
olymorphism who exhibit a retarded ability for
he feedback control of NE release from the
eurons and release excessive amounts of NE in
he synaptic cleft demonstrate a higher delayed
IBG H/M ratio. It is surmised that an increased
ctivity of hNET1 serves as a protective molec-
lar adaptation to partially offset the deleterious
onsequences of an incessant bombardment of
he myocyte with toxic amounts of NE. However,
uch compensatory mechanisms are gradually
verwhelmed, and persistent NE excess leads to
eta-adrenoceptor desensitization and worsening
f HF. Data from transgenic models of exagger-
ted NE release support the importance of NE
euptake mechanisms. Three months after aortic
anding, dramatically reduced survival was ob-
erved in alpha2A-knockout (52%) and alpha2C-
nockout (47%) mice owing to HF with en-
anced LV hypertrophy, myocardial fibrosis, and
levated circulating catecholamines, compared
ith wild-type and alpha2B-deficient animals
86%).
Multiple experimental studies have demonstrated
hat genetic alterations in the NE receptors or their
ownstream signaling pathways may be associated
ith cardiomyopathy, with the myocytes possibly
he innocent victims. A cardiomyocyte-specific
ransgenic overexpression of Gq results in mal-
daptive myocardial hypertrophy and is also associ-
ted with reproducible peripartum cardiomyopathyFigure 1. N
Synaptic C
AC  aden
mine; DHPnd HF; inhibition of Gq-induced signaling at-
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73enuates mitogen-activated protein kinase activa-
ion and cardiac hypertrophy. Genetic polymor-
hism of the rate-limiting enzyme tyrosine
ydroxylase also induces structural changes in the
yocardium. The exact regulation of the enzymatic
ascade through pre-synaptic adrenergic and mus-
arinic receptors, hNET1 efficiency, and deficits of
ntraneuronal monoamine oxidase have not been
lucidated. It is noteworthy that the reduction of
yocardial NE uptake and loss of neuronal NE in
F is not due to the loss of structural integrity of
he cardiac sympathetic nerves, as exemplified by
he unaffected expression of the pan-neuronal pro-
ein gene product 9.5.
Evolutionarily, the sympathetic neurons, as
Figure 2. hNET1 in Cardiomyopathic and Normal Human Hearts
(A) Immunoblot analysis for the assessment of human norepinephr
cardiomyopathic hearts as compared with control human hearts (1
each well was conﬁrmed by glyceraldehyde 3-phosphate dehydrog
immunoblot (Fluor-S MultiImager; Bio-Rad, Hercules, California) are
bands’ mean  SEM (*p  0.05) of 4 IDCM, 4 ISCM, and 8 control h
each sample. (C) The hNET1 glycosylation analysis demonstrated th
hearts was glycosylated, which bound and precipitated with con-A
bound to con-A Sepharose beads remained in the supernatant. GAP
trary unit; IDCM  idiopathic dilated cardiomyopathy; ISCM  ischeompared with the parasympathetic neurons, are urimitive. Unlike parasympathetic neurons,
hich have evolved with cholinesterase protec-
ion, sympathetic neurons rely completely on the
euronal reuptake mechanism to manage NE
xcess and hence are easily overwhelmed. In
bsence of a metabolic inhibitor of NE in the
ynaptic cleft, the excess NE results in adreno-
eptor modulation, myocyte apoptosis (14), and
yocellular loss, further worsening myocardial
unction. It seems that we pay the price for the
ack of evolution in the sympathetic system.
Nerve growth factor overexpression in mice
acilitates NE reuptake and prevents onset of HF.
njection of nerve growth factor into the stellate
anglia of rats with HF resulted in improved NE
ransporter 1 (hNET1) expression demonstrates decreased levels in
trol and 2 cardiomyopathy sample is shown). Equal protein in
e (GAPDH) protein level. (B) Densitometric analyses of hNET1
essed as a bar graph and represent the intensity of the hNET1
ts. Values were corrected by the respective values of GAPDH for
ost of the hNET1 protein in cardiomyopathic and control human
harose beads (pellet); barely detectable unglycosylated hNET1 not
immunoblot conﬁrmed equal protein in each well. AU  arbi-
cardiomyopathy.ine t
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74mprovement in LV function (15); this NE con-
olidation occurred without any change in the
umber of sympathetic nerves. Similarly, overex-
ression of NET1 resulted in marked improve-
ent of HF in a rabbit model (16). The NET1
ene transfer normalizes not only protein expres-
ion of the NET1 but also beta1-adrenergic
eceptors and sarcoplasmic reticulum Ca2-
TPase, thus replicating some of the molecular
ffects that typically accompany pharmacologi-
ally managed HF. Another important finding
Figure 3. hNET1 Before and After LVAD Placement in Human H
(A) Immunoblot showed very low levels of hNET1 protein in pre
increased in post-LVAD (1 representative sample is shown). Equa
Densitometric analyses of hNET1 immunoblot from 5 paired pre-
post-LVAD myocardial samples. Values were corrected by the res
Figure 2.91–9. ity and mortalityyocardial tissue. These experiments suggest
hat modulating hNET1 expression may serve as
n attractive alternative therapeutic target in the
anagement of HF and may lead to development
f pharmacologic agents that facilitate NE re-
ptake mechanisms in the myocardium.
eprint requests and correspondence: Dr. Jagat Narula,
niversity of California Irvine, Division of Cardiology,
01 The City Drive, Bldg 53, Room 100, Route 81,
s
ventricular assist device (LVAD) sample, which were markedly
otein in each well was conﬁrmed by GAPDH protein level. (B)
post-LVAD samples showed restoration of hNET1 levels in
tive values of GAPDH for each sample. Abbreviations as inwas the complete recovery of NE uptake by LV Orange, California 92868-4080. E-mail: narula@uci.edu.1
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